Medicines Co. (MDCO) call put ratio 5.9 calls to 1 put into acquired by Novartis for $9.7B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform
November 25, 2019 8:10 PM ESTSVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).
For an analyst ratings summary and ratings history on The Medicines Company... More
